P. Moseley

发表

Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy

I. Ellis, A. Green, E. Rakha, 2018, Breast Cancer Research and Treatment.

Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio‐resistance in breast cancer

I. Ellis, A. Green, N. Curtin, 2016, Molecular oncology.

Untangling the ATR‐CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer

Graham Ball, Devika Agarwal, Ian O Ellis, 2015, Molecular oncology.

HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer

G. Ball, I. Ellis, R. Rees, 2014, British Journal of Cancer.

PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.

E. Rakha, R. Ali, I. Miligy, 2020, Cancer letters.

High mobility group protein B1 is a predictor of poor survival in ovarian cancer

Nolan, C. Nolan, Christopher, 2017, Oncotarget.

The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective review.

D. Rea, D. Eccles, M. Kerin, 2018, Breast.

ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.

E. Rakha, M. Toss, K. A. Mesquita, 2019, Gynecologic oncology.

Bcl2 expression and prediction of outcomes to anthracycline-based neoadjuvant chemotherapy in ER-positive breast cancer and to nonanthracycline adjuvant therapy.

I. Ellis, J. Reis-Filho, A. Green, 2011, Journal of Clinical Oncology.

Bcl2 as a surrogate prognostic and predictive marker in triple-negative breast cancer.

I. Ellis, J. Reis-Filho, A. Green, 2011, Journal of Clinical Oncology.

Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings.

G. Ball, I. Ellis, S. Chan, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapy

G. Ball, I. Ellis, S. Madhusudan, 2013, Breast Cancer Research and Treatment.

The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2

G. Ball, I. Ellis, R. Rees, 2017, Oncotarget.

Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response–Targeted Therapies in Breast Cancer

I. Ellis, A. Tutt, A. Green, 2017, Molecular Cancer Therapeutics.

DNA polymerase β deficiency is linked to aggressive breast cancer: A comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts

G. Ball, I. Ellis, C. Caldas, 2014, Molecular oncology.

ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers

G. Ball, S. Madhusudan, C. Coveney, 2014, BBA clinical.

Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase Inhibition Is Synthetically Lethal in XRCC1 Deficient Ovarian Cancer Cells

C. Seedhouse, S. Madhusudan, R. Sultana, 2013, PloS one.

Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer

S. Rutella, G. Foulds, A. Pockley, 2018, Front. Immunol..

T Cell Density and Location Can Influence the Prognosis of Ovarian Cancer

A. Al-Attar, P. Moseley, M. Shehata, 2010, Pathology & Oncology Research.

DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers

I. Ellis, A. Green, E. Rakha, 2015, Oncotarget.

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer

I. Ellis, A. Green, E. Rakha, 2014, Breast Cancer Research and Treatment.

Characterisation of HER heterodimers in breast cancer using in situ proximity ligation assay

I. Ellis, A. Green, E. Rakha, 2014, Breast Cancer Research and Treatment.

Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer

I. Ellis, S. Madhusudan, P. Moseley, 2013, Breast Cancer Research and Treatment.

Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers.

G. Ball, I. Ellis, A. Green, 2016, Carcinogenesis.

P4-09-11: Kinesin Family Member 2C (KIF2C) Is a New Surrogate Prognostic Marker in Breast Cancer (BC).

I. O. Ellis, Christophe Lemetre, I. Ellis, 2011 .

Topo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer

I. Ellis, A. Mukherjee, E. Rakha, 2010, British Journal of Cancer.

Calpain‐1 is associated with adverse relapse free survival in breast cancer: a confirmatory study

I. Ellis, A. Boddy, Stewart G. Martin, 2016, Histopathology.

Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer

G. Ball, I. Ellis, C. Caldas, 2014, Molecular oncology.

Dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) and survival in breast cancer: a retrospective analysis of protein and mRNA expression

G. Ball, I. Ellis, A. Green, 2019, Scientific Reports.

SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.

G. Ball, I. Ellis, R. Rees, 2016, The Lancet. Oncology.

Molecular disruption of DNA polymerase β for platinum sensitisation and synthetic lethality in epithelial ovarian cancers

E. Rakha, N. Mongan, S. Narayan, 2021, Oncogene.

Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers

G. Ball, I. Ellis, A. Green, 2014, Breast Cancer Research and Treatment.

The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer

E. Rakha, S. Chan, S. Madhusudan, 2019, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

High mobility group protein B1 is a predictor of poor survival in ovarian cancer

C. Nolan, P. Moseley, S. Deen, 2017, Oncotarget.

Is There a Role for Base Excision Repair in Estrogen/Estrogen Receptor-Driven Breast Cancers?

I. Ellis, A. Green, S. Madhusudan, 2014, Antioxidants & redox signaling.

SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment

I. Ellis, A. Green, E. Rakha, 2019, British Journal of Cancer.

Clinicopathological Significance of ATM-Chk2 Expression in Sporadic Breast Cancers: a Comprehensive Analysis in Large Cohorts

G. Ball, I. Ellis, A. Green, 2014, Neoplasia.

Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer

G. Ball, I. Ellis, A. Green, 2015, Molecular Cancer Therapeutics.

Abstracts from the 4th ImmunoTherapy of Cancer Conference

R. Rees, F. Regnier, A. Trautmann, 2017, Journal of Immunotherapy for Cancer.

RECQL4 helicase has oncogenic potential in sporadic breast cancers

G. Ball, I. Ellis, A. Green, 2016, The Journal of pathology.

Ataxia Telangiectasia Mutated and Rad 3 Related ( ATR ) Protein Kinase Inhibition Is Synthetically Lethal in XRCC 1 Deficient Ovarian Cancer Cells

C. Seedhouse, S. Madhusudan, S. Chan, 2017 .

Targeting BRCA1‐BER deficient breast cancer by ATM or DNA‐PKcs blockade either alone or in combination with cisplatin for personalized therapy

G. Ball, I. Ellis, C. Caldas, 2015, Molecular oncology.

The relationship of CDK18 expression in breast cancer to clinicopathological parameters and therapeutic response

E. Rakha, R. Ali, S. Madhusudan, 2018, Oncotarget.

ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers

G. Ball, A. Green, E. Rakha, 2019, Cancers.

Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor–Positive Breast Cancer

G. Ball, I. Ellis, S. Lakhani, 2020, JAMA network open.

A retrospective study of SPAG 5 as a novel potentially actionable oncogene , prognostic biomarker and chemotherapy sensitivity predictor :-an integrated genomic , transcriptomic and protein analysis of 10 , 000 Breast Cancers

Graham, I. Ellis, R. Rees, 2016 .

Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer

G. Ball, I. Ellis, S. Pinder, 2014, Clinical Cancer Research.

HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis

G. Ball, I. Ellis, R. Rees, 2015, Clinical Cancer Research.

Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer

G. Ball, I. Ellis, S. Pinder, 2014, Clinical Cancer Research.

Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer

G. Ball, I. Ellis, C. Caldas, 2014, Molecular oncology.

Topo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer

I. Ellis, A. Mukherjee, E. Rakha, 2010, British Journal of Cancer.

RECQL4 helicase has oncogenic potential in sporadic breast cancers

G. Ball, I. Ellis, E. Rakha, 2016, The Journal of pathology.